KMT2A重排急性淋巴细胞白血病复发后谱系转换一例并文献复习
回顾性分析1例23岁女性KMT2A::AFF1阳性ALL患者,巩固化疗期间复发,经含贝林妥欧单抗方案再缓解后桥接异基因造血干细胞移植,移植后2月余广泛髓外复发,病理示CD19部分缺失、MPO表达且保留KMT2A重排;CD19-CAR-T治疗后再次髓外复发,CD19完全缺失、MPO阳性,诊断为髓系肉瘤,最终放弃治疗。提示抗原靶向免疫治疗后谱系转换可作为耐药与适应机制,需引起临床重视。
要点
- KMT2A重排ALL复发后可出现谱系转换,表现为CD19丢失与MPO表达。
- 抗原靶向免疫治疗(贝林妥欧单抗、CD19-CAR-T)后需警惕谱系转换。
- 谱系转换时KMT2A重排可保留,提示克隆演化而非新发肿瘤。
核心结论
- 抗原靶向免疫疗法后,谱系转换可作为耐药和适应性机制,需引起临床重视。
研究设计与样本
- 回顾性分析1例KMT2A重排ALL复发后出现谱系转换的病例资料,并进行相关文献复习。
主要发现
- 患者女,23岁,初诊ALL(KMT2A::AFF1阳性),巩固化疗期间复发。
- 含贝林妥欧单抗方案化疗再缓解后桥接异基因造血干细胞移植,移植后2个月余广泛髓外复发。
- 髓外肿物免疫组化示CD19表达部分缺失、出现MPO表达,仍保留KMT2A重排。
- CD19-CAR-T治疗后再次髓外复发,CD19表达完全缺失、MPO阳性,诊断为髓系肉瘤。
临床怎么用
- 对KMT2A重排ALL接受抗原靶向免疫治疗者,复发时应重新活检并做免疫组化评估谱系转换。
局限性
- 本文为单例病例报告并文献复习,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To enhance the understanding of lineage switch (LS), we retrospectively analyzed the clinical data of a patient with KMT2A-rearranged acute lymphoblastic leukemia (ALL) who underwent a LS at relapse and reviewed the relevant literature. The patient, a 23-year-old woman, was initially diagnosed with ALL (KMT2A::AFF1-positive). She experienced a relapse during consolidation chemotherapy and achieved a second remission following chemotherapy containing blinatumomab, subsequently bridging to allogeneic stem cell transplantation. Approximately 2 months after transplantation, extensive extramedullary relapse occurred. Immunohistochemical analysis of the extramedullary mass revealed a partial loss of CD19 expression and emergence of MPO expression, whereas the KMT2A rearrangement was retained. After receiving CD19-CAR-T therapy, the patient experienced another extramedullary relapse, at which time complete loss of CD19 expression and positivity for MPO were observed, leading to a diagnosis of myeloid sarcoma. Ultimately, the family opted to discontinue treatment and the patient was discharged to receive care locally. Following antigen-targeted immunotherapy, LS, as a potential mechanism of drug resistance and adaptation, warrants increased clinical attention. 为提高对谱系转换(lineage switch, LS)这一现象的认识,回顾性分析1例KMT2A重排急性淋巴细胞白血病(ALL)复发后出现LS的病例资料,并对相关文献进行复习。患者,女,23岁,诊断ALL(KMT2A::AFF1阳性),巩固化疗期间复发,予以含有贝林妥欧单抗方案的化疗再次缓解后,桥接异基因造血干细胞移植,移植后2个月余广泛髓外复发,髓外肿物病理免疫组化显示,CD19表达部分缺失,并出现MPO表达,但仍保留KMT2A重排;行靶向CD19的嵌合抗原受体T细胞治疗后,再次髓外复发时,CD19表达完全缺失,MPO阳性,诊断为髓系肉瘤。最终患者放弃治疗,返回当地。抗原靶向免疫疗法后,LS作为一种耐药和适应性机制,需引起临床重视。.
引用
- Qiao ZQ, Shi YP, Hu LD, et al. [KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851184. doi:10.3760/cma.j.cn121090-20260228-00114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。